Grup de recerca de biomarcadors en càncer (GReBiC)
- Nombre de publicacions
- 495
Publicacions
-
Rodriguez, JRV; Murillo, SM; Galindo, AR; Subirats, OP; Ortega, JFC
The prognostic value of liver metastases and how affects the applicability of the lung-molGPA in non-small cell lung cancer patients with brain metastases
ANNALS OF ONCOLOGY 32 526-526. .
-
Hassan, M; Patel, S; Sadaka, AS; Bedawi, EO; Corcoran, JP; Porcel, JM
Recent Insights into the Management of Pleural Infection
International Journal of General Medicine 14 3415-3429. .
-
Valdivia, AA; Salva, F; Ros, J; Baraibar, I; Martinez, GA; Gonzalez, NS; Garcia, A; Margalef, NM; Urteaga, JLC; Capdevila, J; Salvia, MAS; Paez, D; Casado, E; Comas, R; Ruiz-Pace, F; Javierre, GV; Eyzaguirre, DAA; Dienstmann, R; Fernandez, MEE; Tabernero, J
Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
ANNALS OF ONCOLOGY 32 547-548. .
-
Valladares-Ayerbes, M; Safont, MJ; Gonzalez-Flores, E; Garcia-Alfonso, P; Aguilar, EA; Munoz, AML; Nogueras, LC; Ferrer, EF; Salas, NR; Aparicio, J; Llanos, M; Trujillo, OAC; Caceres, PP; Cruz-Hernandez, JJ; Fernandez, MS; Salvia, AS; Garcia-Carbonero, R; Sureda, BM; Conesa, MAV; Vila, AL
Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
ANNALS OF ONCOLOGY 32 560-560. .
-
Jimenez, MM; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De la Haba, J; Ramos, M; Corsaro, M; Kahan, Z; Gil-Gil, M
Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
ANNALS OF ONCOLOGY 32 457-458. .
-
Benavides, M; Gomez-Espana, A; Garcia-Alfonso, P; Garcia, C; Vieitez, JM; Sureda, BM; Rivera, F; Aguilera, MJS; Esteve, AA; Ortega, MG; Valladares-Ayerbes, M; Mena, AC; Gonzalez-Flores, E; Robles, L; Salvia, AS; Alonso, V; Viladot, CM; Asensio-Martinez, E; Diaz-Rubio, E; Aguilar, EA
Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
ANNALS OF ONCOLOGY 32 544-544. .
-
Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S; Paré L; Escrivá-de-Romaní S; Manso L; Adamo B; Martínez E; Cortés J; Vazquez S; Perelló A; Garau I; Melé M; Martínez N; Montaño A; Bermejo B; Morales S; Echarri MJ; Vega E; González-Farré B; Martínez D; Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
CLINICAL CANCER RESEARCH 26 5820-5829. .
-
Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA
Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.
Cancers 12 1-28. .
-
Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
BREAST CANCER RESEARCH 22 124-124. .
-
Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and =3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
ESMO Open 5 -. .
-
Porcel JM
PILOTing towards a RAPID predictor of mortality for infectious pleural effusions.
EUROPEAN RESPIRATORY JOURNAL 56 -. .
-
Sorolla, A; Sorolla, MA; Wang, E; Ceña V
Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment.
Expert Opinion on Drug Delivery 17 1-17. .
